What question did this study set out to answer?

This research aims to explore the anti-leukemic effects of hesperadin and chidamide on T-cell acute lymphoblastic leukemia (T-ALL).

December 8, 2025Blood

Hesperadin, an aurora B kinase inhibitor, synergizes with chidamide to suppress T-cell acute lymphoblastic leukemia by targeting c-MYC

View Full Paper

Ask AI

Bookmark

Authors

ZWZhaoxing WuMinistry of Education of the People's Republic of China

Discussion

Member takes

Implication

In vitro and in vivo analyses reveal that hesperadin and chidamide synergistically reduce tumor growth in T-ALL by promoting apoptosis and impacting cell cycle.

Key Points

This research aims to explore the anti-leukemic effects of hesperadin and chidamide on T-cell acute lymphoblastic leukemia (T-ALL).
Evaluated cytotoxicity of hesperadin and chidamide in T-ALL cell lines using CCK-8 assays.
Assessed in vivo efficacy using T-ALL xenograft models.
Calculated IC₅₀ values in GraphPad Prism and analyzed drug synergy with CompuSyn.
Used flow cytometry and Western blot for evaluating apoptosis and cell cycle changes.
Conducted cycloheximide pulse-chase assays to assess MYC protein turnover.
Hesperadin exhibited potent cytotoxicity in T-ALL cells (IC₅₀: 0.14–0.4 µM), inducing apoptosis via Bax upregulation and downregulation of BCL2/MCL1.
Hesperadin caused G₂/M arrest with decreased CDK1 and Cyclin B levels.
Combined treatment significantly inhibited T-ALL cell proliferation with a drug synergy indicating CI < 1.0 across all lines.
The combination further reduced MYC protein levels and significantly suppressed tumor growth in vivo.

Cite This Study

Zhaoxing Wu (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2cb https://doi.org/10.1182/blood-2025-6828

View Full Paper

Ask AI

Bookmark

Implication

In vitro and in vivo analyses reveal that hesperadin and chidamide synergistically reduce tumor growth in T-ALL by promoting apoptosis and impacting cell cycle.

Hesperadin, an aurora B kinase inhibitor, synergizes with chidamide to suppress T-cell acute lymphoblastic leukemia by targeting c-MYC

Discussion

Member takes

Implication

Key Points

Cite This Study

Hesperadin, an aurora B kinase inhibitor, synergizes with chidamide to suppress T-cell acute lymphoblastic leukemia by targeting c-MYC

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider